Ab Ultra Short Income ETF (YEAR) 銘柄情報

However the data of current trial submitted for approval is not "in vitro"

It is clear that the "investment of a lifetime* message is not getting out. I hope the longs are not being hornscwaggled.

This is the highest day volume since June 2022. 

HUGE revenue pouring in here, we won't be denied, won't be able the hold it down much longer. 

Milling results soon yet some say that this stock is garbage etc have been here as long as me or longer so that would mean plenty of time to see the patterns and make some really good money....but I bet that they haven't....so it is a bit of a conundrum....why wouldn't they when obviously given the

No...all biotechs are up based on gene editing company success it move the index 

Need to Curb Your Enthusiasm just because the share price jumped all the way to $0.0166 share price,
-$0.0015 day change. Isn't that great? We will be heading to Mars soon....no less in Elon Musk's rocket ship or to hell in ________ (add your own).

PDYNW - Nice move today! I will consider buying dips.

TC, I get that. I just meant that in looking at what Italy pays for other drugs, what Amarin wants for Vazkepa is substantially more than MOST drugs on the list.

I'm not talking about the cost to patients, but the cost to the government.

If Vazkepa cost $15 to sell to

BTW, the three companies with approved PD1 inhibitors, which is what the U.S. patent office tried to narrow the combo patent to, are:

Merck = Keytruda

Opdivo = Bristol

Libtayo = Regeneron.
Thanks very helpful.

1 buy of 20k will work the same as 2 buys of 10k on squeeze day, no?

NO!!!!!

On squeeze day your first buy order will be much much lower than all subsequent ones...

For example, on Squeeze day (approval) if your first early open trade gets executed at 1.0

Gaetz is out, my opinion has been he was never really going to be in the position, as it was cover to let him resign from the House before the severe reprimands which could have ruined his chances of a future career. Trump also could now argue he tried to put a pot friendly guy in the office and it

I wonder if .0011 is a good entry? Fishing time. 🎣

Strong buy at ask 0.0002, paint sell at bid 0.0001. 0.0002 2mm shares will be gone soon.

The world will become safer when the ‘adults in the room’ are… gone

By Jack Hellner


When Biden and his team of incompetents took over, the media cheered that finally the adults were back in the room; well thankfully, the “children” will be back soon and the U.S.

I think they think that announced participation in a hot industry segment should entitle them to valuation levels of those hot industry segment leaders. Despite ALWAYS having virtually no revenue.

Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?

BID building here but...you KNOW what will come next......this is the type of chit that needs to stop for us to move up above .0003!

Why hasn't this historic moment made any mainstream press?
x / twitter and company generate PRs mean nothing.
You are repeating yourself over and over. Do you know Vic? You called him "benign" a while back.

If it was DCVax the 2016 paper would cite Liau or Prins as they are the leaders in the field of Dendritic-cell-based vaccines.

They had several papers published before 2016.

It doesn't so it isn't DCVax.

From another poster: “Evotec has already said no thanks. Wall Street said no thanks. When Halozyme management says ok forget about it, we go up $10. We are waiting Ms Helen.”

Can you bring in the update your referencing(please).

No. It seems all right to me.

TRNR....CISO....MULN.........................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

Sometimes you make no sense.